Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03462212
Title Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25)
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Fondazione Policlinico Universitario Agostino Gemelli IRCCS

ovarian carcinosarcoma

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer

ovarian endometrial cancer

ovarian serous carcinoma


Bevacizumab + Carboplatin + Paclitaxel + Rucaparib

Carboplatin + Paclitaxel + Rucaparib

Bevacizumab + Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.